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Abstract
Background: The impact of tumor differentiation on the behavior and response of sinonasal neuroendocrine
carcinoma is unknown.
Methods: We performed a retrospective review of the patients treated for neuroendocrine carcinoma (NEC) of the
nasal cavity or paranasal sinuses from 1992 to 2008 at MDACC.
Results: The results of our study suggest that pathologic differentiation may not be a critical factor in the clinical
management of patients with NEC of the sinonasal tract. This is in contrast to laryngeal and lung NEC for which
pathological differentiation has traditionally guided clinical management.
Conclusion: Mutlimodality approach should be the cornerstone of treating sinonasal NEC regardless of their
differentiation. Specifically, RT may provide durable local control for patients with moderately differentiated NEC if
resection is not feasible or desirable, while surgical resection can benefit patients with chemo-resistant or radio-
resistant disease.
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Introduction
Neuroendocrine neoplasms are classified into well-dif-
ferentiated (typical), moderately differentiated (atypical
carcinoids), and poorly differentiated (small and non-
small cell types). Well- and, to a lesser extent, moder-
ately differentiated neuroendocrine carcinomas carry
better prognosis with low metastatic rates and better
survival [1-4], while poorly differentiated neuroendo-
crine carcinomas are characterized by rapid and fatal
outcome prognosis. Treatment recommendations for
this entity vary considerably due largely to a lack of con-
sensus and variable pathological classification.
The majority of neuroendocrine carcinomas in the
head and neck region arise in the larynx and constitute
the second most common malignancy after squamous
carcinomas [5,6]. The treatment of laryngeal neuroendo-
crine carcinomas is generally based on tumor differen-
tiation status where well and moderately differentiated
tumors are treated surgically and the poorly differen-
tiated are managed by radiation and/or chemother-
apy [6-9]. Primary neuroendocrine carcinomas of the
sinonasal tract are rare and represent a histological
spectrum of differentiation [10-12]. Because of their
infrequency and overlapping pathologic features with
other entities, studies investigating the effect of differen-
tiation status on clinical behavior and management of
patients with these tumors remained unaddressed [10].
We present a series of 20 patients with neuroendo-
crine carcinoma of paranasal sinuses at MD Anderson
Cancer Center to evaluate whether differentiation may
affect treatment and outcomes of these patients.
Patients and Methods
We performed a search of the head and neck pathology,
surgery and radiation oncology databases at the Univer-
sity of Texas M. D. Anderson Cancer Center for
patients diagnosed and treated for neuroendocrine carci-
noma of the nasal cavity or paranasal sinuses from 1992
to 2008. A waiver of consent was obtained from the
Institutional Review Board and patient confidentiality
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preserved. Information was obtained by retrospective
chart review from the in-house electronic medical
records system. The clinicopathological, treatment and
follow-up information were reviewed. Some of the
patients received their entire course of treatment at our
institution, while others were initially treated at other
facilities and underwent salvage therapy at MD Ander-
son. A total of 41 patients treated for neuroendocrine
carcinoma of the paranasal sinuses were identified. 21
patients were excluded due either to loss to follow up or
lack of the pathological materials. Twenty patients with
available diagnostic materials and full records for follow-
up comprised the cohort of this study. All hematoxylin
and eosin and immunostained markers for keratin and
endocrine markers were reviewed independent of the
original diagnosis. Complete agreement between the
initial diagnosis and the re-evaluation that the selected
case represent NECs. Sites of primary malignancy were
specifically limited to nasopharynx, nasal cavity, skull
base, maxillary, ethmoid, and sphenoid sinuses. The
patients’ records were reviewed for the following para-
meters: age, sex, race, symptoms, radiological features,
presenting symptoms, site of tumor and local extension,
surgical approaches and extent of resection, adjuvant
therapies, treatment complications, and patient out-
comes, including dates of death, last follow-up, and
local, regional, and distal failures. Patients were staged
according to the American Joint Committee on Cancer
(AJCC) TNM 2002 staging classification of the nasal
cavity and the paranasal sinuses. Treatment modalities
for each individual patient at MDACC were determined
by a multidisciplinary physician team based on clinico-
pathological features and prior treatment, if present.
The extent of surgery was assessed for presence of com-
plete gross resection vs. subtotal resection. Locoregional
failure was defined as relapse at primary sites or contig-
uous lymphatic drainage basins. Disease free survival
was calculated from the last date of treatment to either
locoregional or distant failure or date of last follow-up if
there was no evidence of failure. Overall survival was
calculated from the last date of treatment to either date




Table 1 presents the clinical and demographic informa-
tion on patients with sinonasal neuroendocrine carci-
noma. There were 11 men and 9 women, with a mean
age of 49.2 years. For those patients in whom this infor-
mation was available, mean time from clinical signs to
diagnosis was 10 months, and initial symptoms included:
nasal congestion (n = 10, 50%), epistaxis (n = 6, 30%),
headache (n = 3, 15%), persistent sinusitis (n = 3, 15%),
and neck mass (n = 2, 10%) (Table 1). In the group of
patients with poorly differentiated NE carcinoma, one
patient had reported receiving radiation to the head and
neck in childhood for tonsillitis, and another patient had
a retinoblastoma gene mutation with a previous diagno-
sis of bilateral retinoblastomas and breast cancer.
Pathologic evaluation
The independent histopathologic evaluation focusing on
differentiation classified seven as moderately differen-
tiated (atypical carcinoid) and 13 as poorly differentiated
(small and non-small cell). (Table 1, Figure 1). Atypical
carcinoids were characterized by formation of glandular,
organized cell nest or cords of tumor cells. Tumors also
manifested cellular pleomorphism, increased mitotic fig-
ures and occasional small areas of necrosis. In contrast,
poorly differentiated tumors were lacking any differen-
tiation. Both subtypes were positive for keratin and at
least one of neuroendocrine markers.
Stage
Of the patients with MDNEC, one (14%) had stage I
(T1N0M0), 5 patients (71%) presented with stage IV,
and one (14%) had an Tx stage due to an outside resec-
tion (Tables 1 and 2). Two (29%) presented with nodal
disease (N2b and N1). Patients with PDNEC were staged
as follows: two (15%) had stage II (T2N0M0), one (8%)
had stage III (T3N0M0), nine (69%) presented with
stage IV (six with T4bN0M0, two with T4aN0M0, one
with T4bN1M0), and one (8%) had an unknown stage
due to an outside resection. Only one patient (8%) pre-
sented with nodal disease (N1).
Treatment modalities
Multimodality approach, using surgical resection, sys-
temic chemotherapy and radiation, was used in the
treatment of most patients (Table 2) Surgical treatment
included craniofacial resection (n = 8, 40%), medial
maxillectomy (n = 2, 10%), ethmoidectomy (n = 3, 15%),
and sphenoidectomy (n = 2, 10%). Neck dissection was
performed in 2 patients with nodal metastasis. For two
of the patients who underwent surgery the specific type
of resection was not known due to lack of available
records. Of the 15 patients undergoing surgical resec-
tion, subtotal resection was documented in 6 patients
(40%). The resection of one poorly differentiated neu-
roendocrine carcinoma was complicated by a CSF leak,
pneumocephalus, and pontine hemorrhage, which led to
the eventual demise of the patient after a protracted ill-
ness. No other major complication was noted after sur-
gical procedures.
Chemotherapy was administered in neoadjuvant, concur-
rent and adjuvant settings, as well as part of salvage treat-
ment. Chemotherapy treatment included cisplatinum and
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etoposide (n = 9), carboplatin and etoposide (n = 4), cis-
platinum and 5-fluorouracil (n = 2), and Taxotere (n = 1).
Radiatiotherapy (RT) was administered as part of defi-
nitive, adjuvant or salvage treatment. The technique and
doses varied in part because of the long span of treat-
ment years. Unfortunately, treatment details were not
available in some cases because the treatment took
place at an outside facility or before electronic medical
record system was instituted. The available treatment
details indicated that radiation was delivered by either
3D conformal radiation therapy or intensity modulated
radiation therapy. All patients with the exception of
patient 6 who did not finish his prescribed course, were
treated to at least 60 Gy.
Outcomes
Follow-up interval for surviving patients ranged from 13
to 172 months (median 60 months). Recurrences were
predominantly locoregional, with only one patient in
each group having distant metastases. 4 patients (57%)
in MDNEC group and 6 patients (46%) in PDNEC
group suffered from recurrences. In the MDNEC group,
patient 7 had local recurrence at 80 months. Patients 5
and 6 had cervical lymph node (LN) recurrence at 46
and 125 months, respectively. Patient 2 had dural metas-
tases identified at 21 months. In the PDNEC group,
patients 13, 15 and 18 had persistent disease with no
radiographic evidence of remission. Patient #17 had
local recurrence at 11 months and patient #16 suffered















none AdRT none none NED (166)
2 F/67 mod T4aN2bM0
(IVA)




3 F/43 mod T1N0M0 (I) SPH, ETH none AdRT none none NED (31.3)
4 M/46 mod T4bN1M0
(IVb)
none NAC CRT none none NED (16.6)
5 M/54 mod T4N0M0
(IV)
STR ES Concurrent AdCRT Bilateral cervical
LN (46)
ND, AdRT NED (107)
6 M/47 mod T4bN0M0
(IVB)
STR CFR none AdRT Ipsilateral level I
(125)
ND, AdCRT NED (172)
7 M/54 mod TxN0M0 S AdC AdRT local (80) NAC/RT/AdC, CFR DOD (119)
8 M/78 poorly T4bN0M0
(IVB)
S none none none none NED/Dead
(77)
9 F/24 poorly T4bN0M0
(IVB)
none NAC; AdC RT none none NED (136)
10 F/47 poorly T4bN1M0
(IVB)
none NAC RT leptomeningeal
dz (4.1)
none DOD (13)
11 F/38 poorly T4bN0M0
(IVB)
CFR none AdRT none none NED (47.5)
12 M/53 poorly TxN0M0 STR ETH AdC;
concurrent
AdCRT none none NED (17.8)
13 M/51 poorly T3N0M0
(III)
none NAC; AdC RT persistent (0) none DOD (17)
14 F/57 poorly T4aN0M0
(IVA)
CFR, SPH NAC none none none DOC (16)
15 M/70 poorly T4bN0M0
(IVB)
STR ETH AdC none persistent (0) CFR/RT DOD (16)
16 F/33 poorly T2N0M0 (II) CFR none AdRT Ipsilateral
levels I-V (5)
ND, AdRT NED (149)
17 M/38 poorly T2N0M0 (II) none NAC RT local (11) ETH/MM/SPH, AdCRT DOD
(37.5)
18 F/60 poorly T4bN0M0
(IVB)
STR CFR AdC AdRT persistent (0) AdC NED/Dead
(112)
19 F/38 poorly T4aN0M0
(IVA)
CFR none AdRT none none NED (168)
20 M/64 poorly T4bN0M0
(IVB)
STR CFR Concurrent AdCRT none none NED (63)
AWD = alive with disease; NED = no evidence of disease; DOD = dead of disease; DOC = dead of treatment complications. S = resection of unknown type, RT =
radiation therapy, AdRT = adjuvant radiation therapy, NAC = neoadjuvant chemotherapy, AdC = adjuvant chemotherapy, AdCRT = adjuvant chemoradiation. CFR
= Craniofacial Resection, ETH = Ethmoidectomy, SPH = Sphenoidectomy, MM = Medial Maxillectomy, STR = Subtotal Resection.
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from cervical LN recurrence at 5 months. Median over-
all disease free survival (DFS) for both groups was 23.6
months while overall survival (OS) was 58.6 months.
MDNEC
The median DFS and OS were 46 months and 107
months respectively. All patients received radiation ther-
apy as part of their treatment. Those patients, for whom
resection was part of management, had a median DFS
of 63 months and a mean OS of 113 months (Table 2).
Those patients with subtotal resections had a median
DFS of 85 months and a mean OS of 139 months. 5
patients (71%) were alive at last follow-up. The patient
with the poorest DFS and OS (11 and 17 months
respectively) was the patient that did not have a surgical
resection, and instead received definitive CRT (Table 2).
PDNEC
The median DFS and OS were 11 months and 47.5
months respectively. Ten out of thirteen patients
received RT as part of their treatment and their median
DFS was 13.3 months and OS was 55 months. The four
patients who did not undergo surgery but instead
received definitive chemoradiation had a median DFS of
7.6 months and OS of 27.3 months (Table 2). The nine
patients who received surgery as part of their treatment
had a median DFS of 16 months and a mean OS of 63
months. 8 patients (62%) were alive at last follow up.
Discussion
Sinonasal NEC is a rare malignancy, the clinical behavior
of which is not well known. The paucity of published lit-
erature on this subject had been compounded by the fact
that previous studies of sinonasal NEC have included a
subset of broad spectrum of neuroectodermal tumors,
including olfactory neuroblastoma, small cell neuroendo-
crine carcinoma and sinonasal undifferentiated carci-
noma. Management decisions for these rare sinonasal
NEC’s often have to be based on analogous treatment
principles for NEC of other anatomical sites, such as lung
Figure 1 Photomicrograph of a moderately differentiated (A) and poorly differentiated (B) neuroendocrine carcinomas of the
sinonasal tract. Figure 1C shows a chromogranin positivity in the cytoplasm of tumor cells of a MDNEC and Figure 1D displays synaptophysin
positive PDNEC.
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and larynx, where histopathological differentiation is gen-
erally considered a key element to guide therapeutic deci-
sions. To the authors’ knowledge, this is the first paper to
compare clinical history, recurrence patterns, and treat-
ment outcomes between moderately and poorly differen-
tiated sinonasal NEC. Focused pathologic review was
conducted to determine the neuroendocrine differentia-
tion was accurate status of these tumors.
Multimodality approach was utilized in treatment of
most patients at our institution regardless of the level of
differentiation. Only one patient in the MDNEC group
did not undergo surgery as part of his initial treatment,
and his DFS was much lower (11 months) compared to
the rest in the group who underwent a resection (63
months) (Table 2). In the PDNEC group, nine patients
(69%) underwent surgical resection as part of initial
treatment and their DFS was also greater compared to
those in the group who did not, 16 vs. 7.6 months
(Table 2). Interestingly, the four patients in the PDNEC
group who had persistent disease or local failure had
non-surgical based treatment or an incomplete surgical
resection. Since surgical intervention in the head and
neck is not without substantial risks and morbidity, the
extent of surgical intervention should be considered in
the evaluation. The role of minimally invasive endo-
scopic resection was not directly assessed in this study,
but utilizing this approach can limit surgical morbidity
without compromising oncologic outcomes.
All patients with MDNEC received RT as part of their
initial treatment, and all but one patient underwent sur-
gery. Patients with complete local control had all received
RT with only one patient who had a local recurrence at
80 months after undergoing surgery with adjuvant RT
and chemotherapy. Ten patients (77%) in PDNEC group
had RT as part of their initial treatment. Of the three
patients who did not have RT, only one had persistent
disease and was treated with a re-resection at MDACC
and adjuvant chemo-re-irradiation and died of disease.
DFS was greater for all patients who underwent resection
as part of their initial treatment (Table 2). Our results
suggest that pathological differentiation may not be a cri-
tical factor in the clinical management of patients with
these tumors. In our small series, 1 year, 5 year and 10
year local control rates for neuroendocrine carcinomas
were comparable. Although MDNEC manifested a less
aggressive course than its poorly differentiated counter-
part, our data show that both entities may benefit from a
multi-modality approach. Two patients with PD and one
with MD NEC developed neck recurrences, and none of
these had neck RT, and all three of these patients were
salvaged. In contrast, no patient who had neck irradiation
developed a local recurrence. This suggests that neck in
addition to primary site irradiation should be considered
for patients with both MD and PD NEC’s. One patient
succumbed to leptomenengial disease and another to
dural metastases. RT technique may be important to
reduce such risk with adequate coverage of adjacent
dural pathways of potential spread.
In our study, the majority of recurrences in both
groups were locoregional, suggesting that local control
may be independent of differentiation though the num-
bers are small to make a categorical conclusion. A pre-
vious study of undifferentiated tumors in the sinonasal
region showed that twenty patients with NEC eight suf-
fered from locoregional recurrence while only one
patient died of metastatic disease [13]. In a published
M.D. Anderson experience with sinonasal carcinomas by
Rosenthal et al, locoregional failure for SNEC was 40%
while the rate of distant metastases was 14% [1]. It was
also concluded that RT and surgery appear to play an
important role in treatment of both groups. Although
our analysis suggests that differentiation may have a
prognostic significance in terms of DFS and OS, the role
in the therapeutic response is minimal.
Our findings are in contrast to studies for NEC of the
larynx where MDNEC were refractory to radiation and
chemotherapy, with surgical resection being the primary
method of treatment [5,8]. PDNEC, however, has both
high local recurrence and distant metastasis rates, and is
radiation-responsive, so traditionally the preferred treat-
ment has been systemic chemotherapy and radiotherapy
(RT) [9,13]. Recent studies have demonstrated a benefit
Table 2 Characteristics, presentations, and outcome of
patients with sinonasal moderately differentiated




Age at presentation 47.6 (22-67) 50 (24-78)
M:F ratio 5:2 6:7
Major Presenting Symptoms
Congestion/Sinusitis 3 (43%) 7 (54%)
Epistaxis 3 (43%) 3 (23%)
Hearing loss 1 (14%) 0
Neck mass 0 2 (15%)
Stage
I 1 (14%) 0
II 0 2 (15%)
III 0 1 (8%)
IV 5 (71%) 9 (69%)
DFS
Ch + RT 11 (mon) 7.6 (mon)
RT + Surgery 63 (mon) 16.0 (mon)
• Ch: Chemotherapy.
• MDNEC: Moderately differentiated.
• PDNEC: Poorly differentiated.
• RT: Radiotherapy.
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of multimodality approach for neuroendocrine carcinomas
of the head and neck. A retrospective review of 11 patients
with MDNEC of the larynx treated at M.D. Anderson
Cancer Center, Gillenwater et al. reported that a subset of
these patients’ disease responded to radiation and che-
motherapy [14]. While PDNEC of the head and neck has
traditionally been treated with concurrent chemoradiation
because of the propensity for early spread, there are multi-
ple reports in the literature whereby these malignancies
were treated successfully with surgery alone [15-18]. A dis-
tinction must be made between small cell and non-small
cell types of PDNEC. Two studies of combined modality
treatment with neoadjuvant chemotherapy and high-dose
precision RT for esthesioneuroblastomas and poorly dif-
ferentiated NEC found that craniofacial resection is effec-
tive especially in recurrent or persistent disease [19,20].
Thus, RT may provide durable local control for patients
with moderately differentiated NEC if resection is not fea-
sible, while post-RT surgical resection can benefit patients
with chemo-resistant or radio-resistant disease. One
potential approach that is under study at our institution is
the role of induction chemotherapy in stratifying patients
for either surgical resection of combined chemoradiother-
apy regimens based on response. Further study is neces-
sary to delineate the ideal approach for this disease.
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